SCHEMBL335755

SCHEMBL335755

COc1cc(N2CCNCC2)cc(OC)c1OC

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 3/20 0.62
ACVR1 Q04771 8/20 0.59
TGFBR1 P36897 7/20 0.59
ACVR1B P36896 4/20 0.59
CHRNB2 P17787 2/20 0.58
CHRNA4 P43681 2/20 0.58
KCNH2 Q12809 2/20 0.56
BMPR1A P36894 2/20 0.56
ACVRL1 P37023 2/20 0.56
BMPR1B O00238 1/20 0.56
ABL1 P00519 1/20 0.56
ADRA2A P08913 1/20 0.56
CNR1 P21554 1/20 0.56
DDR1 Q08345 1/20 0.56
PTK6 Q13882 1/20 0.56
MINK1 Q8N4C8 1/20 0.56
SIK2 Q9H0K1 1/20 0.56
MAP3K20 Q9NYL2 1/20 0.56
NLK Q9UBE8 1/20 0.56
TNIK Q9UKE5 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL10572729 0.98 ADRB1 (0.61) ADRB1ACVR1TGFBR1ACVR1BCHRNB2
SCHEMBL19709394 0.84 ADRB1 (0.61) ADRB1ACVR1TGFBR1ACVR1BCHRNB2
SCHEMBL19709420 0.84 ADRB1 (0.61) ADRB1ACVR1TGFBR1ACVR1BCHRNB2
SCHEMBL9829916 0.82 ALDH1A1 (0.55)
SCHEMBL7507944 0.81 ADRB1 (0.62) ADRB1ACVR1TGFBR1ACVR1BCHRNB2
SCHEMBL10690642 0.81 ALDH1A1 (0.53)
SCHEMBL24202082 0.81 ADRB1 (0.57) ADRB1ACVR1TGFBR1ACVR1BCHRNB2
Hydrochloric Acid SCHEMBL8931722 0.80 ADRB1 (0.61) ADRB1ACVR1TGFBR1ACVR1BCHRNB2
SCHEMBL4939296 0.80 ADRB1 (0.61) ADRB1ACVR1TGFBR1ACVR1BCHRNB2
SCHEMBL5245685 0.80 ADRB1 (0.61) ADRB1ACVR1TGFBR1ACVR1BCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092134-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery UNIV JOHNS HOPKINS (US) 2026-04-02 US disclosed
US-12527746-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2026-01-20 US disclosed
EP-4642434-A2 LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2025-11-05 EP disclosed
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same Life Technologies Corporation (US) 2025-11-04 US disclosed
US-12371522-B2 Bioreducible poly (beta-amino ester)s for siRNA delivery THE JOHNS HOPKINS UNIVERSITY (US) 2025-07-29 US disclosed
US-20250136737-A1 MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS THE JOHNS HOPKINS UNIVERSITY 2025-05-01 US disclosed
US-20240263196-A1 Lipid Compositions and Methods for Delivery to Immune Cells Life Technologies Corporation 2024-08-08 US disclosed
US-12049530-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERISTY (US) 2024-07-30 US disclosed
WO-2024145435-A2 LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2024-07-04 WO disclosed
US-20230181742-A1 AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME Life Technologies Corporation 2023-06-15 US disclosed
EP-0277725-A2 4-Aryl-N-[2-(dialkylamino and heterocyclicamino) alkyl]-1-piperazinecarboxamides and their use as anti allergy agents A.H. ROBINS COMPANY, INCORPORATED (US) 1988-08-10 EP disclosed
EP-0269383-A2 1-Aryloxy-4-[(4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents A.H. ROBINS COMPANY, INCORPORATED (US) 1988-06-01 EP disclosed
US-4734416-A ANTIHISTAMINES, CENTRAL NERVOUS SYSTEM CONTROLLING ACTION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-03-29 US disclosed
US-4547504-A Substituted phenyl piperazinyl pyrrolidin-2-ones and related compounds useful as anti-depressants and their use RHONE-POULENC SANTE (FR) 1985-10-15 US disclosed
US-4370329-A Piperazine derivatives as circulation-enhancing substances MERZ & COMPANY (DE) 1983-01-25 US disclosed
US-4370330-A Method of enhancing circulation with piperazines MERZ & COMPANY (DE) 1983-01-25 US disclosed
US-4257952-A PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES STERLING DRUG INC. (US) 1981-03-24 US disclosed
US-4172834-A ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS STERLING DRUG INC. (US) 1979-10-30 US disclosed
US-4062864-A ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE STERLING DRUG INC. (US) 1977-12-13 US disclosed
US-3959309-A ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE STERLING DRUG INC. (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527746-B2 Peptide/particle delivery systems VEGFA, IGF2BP2, MSTN ADRB1 1326/4885ACVR1 1013/4885TGFBR1 1505/4885
US-20230181742-A1 AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME SNRPA, NUDT21, SOAT2 ADRB1 2390/4885ACVR1 3271/4885TGFBR1 4369/4885
US-20250136737-A1 MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS PEF1, FIBP, PARN ADRB1 4466/4885ACVR1 3455/4885TGFBR1 2951/4885
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same SNRPA, NUDT21, SOAT2 ADRB1 2390/4885ACVR1 3271/4885TGFBR1 4369/4885
US-12371522-B2 Bioreducible poly (beta-amino ester)s for siRNA delivery AARS1, SLC43A1, PHAX ADRB1 1085/4885ACVR1 1435/4885TGFBR1 2346/4885
US-12049530-B2 Multicomponent degradable cationic polymers PEF1, FIBP, PARN ADRB1 4466/4885ACVR1 3455/4885TGFBR1 2951/4885
US-20260092134-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery SLC43A1, SLC7A5, SLC7A1 ADRB1 961/4885ACVR1 284/4885TGFBR1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.